Most Liquid Biotech Companies

Cash And Equivalents
Cash And EquivalentsEfficiencyMarket RiskExp Return
1APGE Apogee Therapeutics, Common
109.87 M
(0.04)
 4.43 
(0.18)
2AARD Aardvark Therapeutics, Common
10.12 M
(0.18)
 7.62 
(1.36)
3BNTX BioNTech SE
9.33 B
(0.05)
 3.18 
(0.17)
4REGN Regeneron Pharmaceuticals
7.02 B
(0.02)
 2.04 
(0.05)
5DNA Ginkgo Bioworks Holdings
1.32 B
(0.04)
 7.19 
(0.25)
6ABCL Abcellera Biologics
868.21 M
(0.04)
 4.68 
(0.19)
7MRVI Maravai Lifesciences Holdings
617.45 M
(0.20)
 5.77 
(1.16)
8CNTA Centessa Pharmaceuticals PLC
484.16 M
 0.01 
 3.60 
 0.02 
9VALN Valneva SE ADR
336.22 M
 0.20 
 5.22 
 1.02 
10MOLN Molecular Partners AG
267.13 M
(0.06)
 4.15 
(0.24)
11TARS Tarsus Pharmaceuticals
245.36 M
(0.01)
 3.56 
(0.05)
12CPRX Catalyst Pharmaceuticals
220.79 M
 0.05 
 3.20 
 0.15 
13GNFT Genfit
209.12 M
(0.01)
 3.36 
(0.03)
14ABOS Acumen Pharmaceuticals
189.91 M
(0.15)
 3.85 
(0.56)
15INBX Inhibrx
176.38 M
 0.00 
 3.46 
(0.01)
16TCRX Tscan Therapeutics
125.6 M
(0.20)
 4.29 
(0.85)
17SMMT Summit Therapeutics PLC
121.97 M
 0.06 
 5.46 
 0.35 
18MBIO Mustang Bio
107.37 M
(0.27)
 9.35 
(2.48)
19MNMD Mind Medicine
105.74 M
 0.01 
 5.92 
 0.06 
20TOVX Theriva Biologics
52.27 M
 0.05 
 9.03 
 0.42 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes. Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).